A prospective study has concluded that women of childbearing age with uterine fibroids (UF) who desire to preserve fertility benefit from the combined oral supplementation of vitamin D, epigallocatechin gallate (EGCG) and vitamin B6.
The supplementation was found to reduce the volume of UFs and improve patients' quality of life, without side effects.
“In women of childbearing age, minimally invasive procedures or alternative medical treatments are preferred, avoiding radical abdominal surgery,” wrote the Italian authors in the journal European Review for Medical and Pharmacological Sciences.
The study enrolled 95 women with UFs who were referred to Sandro Pertini Hospital of Rome between April and December 2020. Inclusion criteria were women aged 18 or older within childbearing age and at least one UF with a diameter less than 4 cm detected by vaginal and abdominal ultrasound, along with a fibroid color score between 1 (absence of vascularization) and 2 (peripheral vascularization).
Patients were divided in 2 groups: 41 women were treated daily with 2 tablets of 25 μg vitamin D + 150 mg EGCG + 5 mg vitamin B6 for 4 months; the other 54 women received no treatment (control group).
The total volume and vascularization of UFs were analyzed via ultrasonography.
The treated group at 4 months achieved a significant reduction of 37.9% in total UF volume: from a mean value of 20.55 cm³ at baseline to 12.65 cm³.
The treated group also had a significant reduction in peripheral vascularization: 36.3% pretreatment vs. 28.6% after treatment.
In contrast, the control group had an increase of 5.5% in total UF volume and an increase of 5.5% in peripheral vascularization.
Pelvic pain and bleeding were evaluated as well. In the treated group, the visual analogue scale (VAS) median value improved from 4 at baseline to 2 after treatment (P = .03), whereas the control group showed a value of 4 at both intervals.
Heavy bleeding was reported by patients in both groups, with more of a decrease in the treated group, although the reduction was not statistically significant (P = .09).
The treated group also reported a significant improvement in the questionnaire score for the Short Form Health Survey (SF-36) (mean score pretreatment of 61.86 vs. 80.77 post-treatment) (P < .001).
Likewise, the Patient Global Impression of Improvement (PGI-I) questionnaire revealed a successful result in 85.4% of treated women, with 73.2% stating “very much better” and 12.2% “much better.”
Among smokers treated, there was a 38.49% decrease in total UF volume, which was similar to the entire sample of treated women.
Treated women reported no side effects during the 4 months of evaluation and the supplementation was well tolerated by all.
“Thus, this supplementation may represent a valid alternative to the classic ‘wait and see’ approach and, at the same time, an adjuvant treatment that could be administered along with pharmacological therapies, even before surgery to reduce the occurrence of possible complications,” wrote the authors.
The next step is to acquire a better understanding of how the 3 natural compounds work together synergistically against UFs.
__
Reference
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Pap Talk S4E4: RFA and uterine fibroids with Dr. Jessica Shepherd
March 30th 2022In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.
Listen
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
Physician-patient collaboration for uterine fibroid treatment options
May 12th 2021Contemporary OB/GYN®’s senior editor Angie DeRosa sat down with Ayman Al-Hendy, MD, and Sateria Venable of The Fibroid Foundation, to discuss the role of patient-physician collaboration in uterine fibroid treatment and management options.
Listen
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More
Study finds relugolix-CT Improves HMB in Black women
February 19th 2024Recent research highlights the efficacy and safety of relugolix combination therapy in managing uterine fibroid-associated heavy menstrual bleeding specifically among Black women, demonstrating outcomes comparable to the broader population.
Read More